Reducing inflammation and oxidative stress, SAG administration importantly reduced liver fibrosis, as confirmed by the decreased collagen deposition, assessed by Masson trichrome staining, and the reduced hydroxyproline contents and α-sma and TGF-β expressions, while it restored IL10 levels. The gene discussed is ACTA1; the disease is Hepatic fibrosis.